Category: Thomson Reuters
Here's a look at some of the top Wall Street stories for medical device companies this week: 5 factors affecting the future of medtech; Medtech VC deals post double-digit increases in Q3; Breast implant maker Sientra sets IPO range; GE CEO Immelt: Global experience got Flannery the top spot at GE Healthcare; GI Dynamics proposes 1-for-10 reverse stock split
Venture capital investment in medical device companies rose both in terms of value and volume during the 3rd quarter, according to the MoneyTree report from PricewaterhouseCoopers and the National Venture Capital Assn., based on Thomson Reuters data.
Venture capital shops got behind medtech during the 3rd quarter, increasing their spend and the number of deals compared with the same period last year, according to the MoneyTree report from PricewaterhouseCoopers and the National Venture Capital Assn., based on Thomson Reuters data.
Here's a look at some of the top funding stories for medical device companies this week.
Venture capital investment in medical device companies reportedly throttled back during the 1st quarter, even as the value of medtech deals rose compared with the 4th quarter of 2013.
Venture capitalists put more skin in fewer deals during the 1st quarter, amid an overall decline in life science deals, according to a survey of VC shops.
The number of deals for the medical device & equipment sector dropped 37% to 61 transactions, but the total value of those deals rose 28% to $588 million, according to the MoneyTree report from PricewaterhouseCoopers LLP and the National Venture Capital Assn., based on data provided by Thomson Reuters.
Venture capital investors spent 21% more backing life science startups in 2011 than in 2010, according to PricewaterhouseCoopers; also, VCs in the Valley lose confidence; Greenway Medical prices IPO; does Abbott need a new CEO?; and analysts' ups and downs.
Venture capital funding of life science startups, including biotech and medical device enterprises, rose by 21% last year, according to PricewaterhouseCoopers.
VCs dropped $7.5 billion on 785 life sciences deals during the year, according to a PwC report, "Zigzagging Upward," compiled using data from the PricewaterhouseCoopers LLP/National Venture Capital Assn. MoneyTree Report and Thomson Reuters.